Panacea Biotec Stock Secures Vaccine Supply Order Worth Rs. 20.79 Cr from CMSS

Synopsis: In a fresh government procurement win, Panacea Biotec Limited has received a Letter of Award from the Central Medical Services Society under the Ministry of Health and Family Welfare for supply of Diphtheria and Tetanus Vaccine for Adults and Adolescents.

Shares of a research-based biotechnology and vaccine manufacturing company came into focus after the BSE-listed firm disclosed a government order win dated April 11, 2026. The Letter of Award, issued by CMSS on April 10, 2026, covers the multi-tranche supply of Td Vaccine to the health ministry’s central procurement arm.

With a market capitalization of Rs. 1,974 crore, the shares of Panacea Biotec are trading at Rs. 320 per share, down 2.19 percent from its previous close of 327.15. The LOA from CMSS mandates supply of Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents IP, commercially referred to as Td Vaccine in multiple tranches, commencing September/October 2026 and running through November/December 2028. The aggregate contract value stands at Rs. 20.79 crore.

CMSS functions as the central procurement and distribution agency for health commodities under the Government of India, supplying vaccines and medicines across the national immunisation programme. An award from CMSS therefore comes with sovereign-backed offtake certainty.

A structural advantage over private-sector contracts where the counterparty risk is higher. The staggered delivery schedule across roughly two years also provides a degree of near-term revenue visibility, even if modest at scale. At Rs. 20.79 crore, this order represents roughly 3.4 percent of the company’s TTM consolidated revenue of approx Rs. 606 crore. 

Business Overview

Incorporated in 1984, Panacea Biotec Limited is one of India’s largest vaccine manufacturers. The company is recognised by UN health agencies for its contributions to the Global Polio Eradication Initiative and holds WHO pre-qualified vaccine status. For the quarter ended December 2025, the company reported consolidated revenue of Rs. 165.19 crore and a net profit of Rs. 3.89 crore, compared to a net loss of Rs. 14.01 crore in the preceding September 2025 quarter.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Panacea Biotec Stock Secures Vaccine Supply Order Worth Rs. 20.79 Cr from CMSS appeared first on Trade Brains.